Condition

Adenocarcinoma of the Lung

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 33 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials33

Recruiting0

Common interventions25

Lead sponsors shown15

Clinical trials

33 shown

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaNCT04459078 · 2020-08-26

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungNCT02466568 · 2018-07-01

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma HistologyNCT04046614 · 2018-05-25

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorNCT03041181 · 2017-01-27

Circulating Tumor DNA in Patients at High Risk for Lung CancerNCT02715102 · 2016-06-01

Icotinib for Completed Resected IB NSCLC With EGFR MutationNCT02264210 · 2015-01-01

Telomere Biology in Early Adenocarcinoma of the LungNCT02239432 · 2014-09-01

Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung CancerNCT02288026 · 2014-09-01

Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung CancerNCT01958372 · 2014-08-01

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibNCT02134912 · 2014-08-01

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLCNCT02059967 · 2014-03-01

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor CareNCT01726296 · 2013-01-01

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerNCT01707823 · 2012-10-01

Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the LungNCT01561456 · 2011-12-01

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the LungNCT01218516 · 2011-06-27

Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT01259089 · 2011-04-27

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT01345851 · 2011-03-23

ACTIVE_NOT_RECRUITING

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)NCT00511485 · 2007-08-01

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT01557959 · 2007-07-01

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00368992 · 2006-08-01

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung CancerNCT00369551 · 2006-06-01

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00118183 · 2005-07-01

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerNCT00118144 · 2005-06-01

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerNCT00087412 · 2004-09-01

Photodynamic Therapy in Treating Patients With Lung CancerNCT01668823 · 2004-02-01

Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by SurgeryNCT00049543 · 2002-09-01

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung CancerNCT00021060 · 2002-08-01

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerNCT00040794 · 2002-05-01

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung CancerNCT00042835 · 2002-05-01

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT00020709 · 2001-06-01

Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT00005838 · 2000-03-01

Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung CancerNCT00002852 · 1996-10-01

Common interventions

Leading sponsors

National Cancer Institute (NCI) 12 AIO-Studien-gGmbH 1 Axelar AB 1 Barbara Ann Karmanos Cancer Institute 1 Capital Medical University 1 Endocyte 1 Fox Chase Cancer Center 1 H. Lee Moffitt Cancer Center and Research Institute 1 Hunan Cancer Hospital 1 Jonsson Comprehensive Cancer Center 1 Meir Medical Center 1 Morphotek 1 Nasser Hanna, M.D. 1 Northwestern University 1 Pathway Genomics 1

Trial status mix

COMPLETED21

TERMINATED6

UNKNOWN3

WITHDRAWN2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE218

PHASE18

PHASE35

NA2

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.